TR200003157T2 - Homogeneous pharmaceutical compositions containing abacavir, lamivudine and zidovudine - Google Patents

Homogeneous pharmaceutical compositions containing abacavir, lamivudine and zidovudine

Info

Publication number
TR200003157T2
TR200003157T2 TR2000/03157T TR200003157T TR200003157T2 TR 200003157 T2 TR200003157 T2 TR 200003157T2 TR 2000/03157 T TR2000/03157 T TR 2000/03157T TR 200003157 T TR200003157 T TR 200003157T TR 200003157 T2 TR200003157 T2 TR 200003157T2
Authority
TR
Turkey
Prior art keywords
lamivudine
zidovudine
pharmaceutical compositions
compositions containing
abacavir
Prior art date
Application number
TR2000/03157T
Other languages
Turkish (tr)
Inventor
Currie Robin
Jain Sunil
Wayne Wood Allen
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200003157T2 publication Critical patent/TR200003157T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Abacavir, lamivudin ve zidovudinin antiviral etki saglayan bir miktarda bir homojen kombinasyonunu içeren bir farmasötik bilesim, bu tip bir bilesimi hazirlamak için bir islem, ve bir insan bagisiklik eksikligi virüsü (HIV) enfeksiyonlu hastaya bu tip bir bilesimin uygulanmasini içeren HIV virüsü inhibe edici bir yöntem tarif edilmektedir.An HIV virus inhibitory method comprising a pharmaceutical composition comprising a homogeneous combination of abacavir, lamivudine and zidovudine in an amount that provides antiviral effect, a human immunodeficiency virus (HIV) infected patient. is described.

TR2000/03157T 1998-04-29 1999-04-26 Homogeneous pharmaceutical compositions containing abacavir, lamivudine and zidovudine TR200003157T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9809213.3A GB9809213D0 (en) 1998-04-29 1998-04-29 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
TR200003157T2 true TR200003157T2 (en) 2001-01-22

Family

ID=10831228

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03157T TR200003157T2 (en) 1998-04-29 1999-04-26 Homogeneous pharmaceutical compositions containing abacavir, lamivudine and zidovudine

Country Status (23)

Country Link
EP (1) EP1083932A1 (en)
JP (1) JP2002512979A (en)
KR (1) KR20010043128A (en)
CN (1) CN1411380A (en)
AP (1) AP2000001971A0 (en)
AU (1) AU4135599A (en)
BR (1) BR9910071A (en)
CA (1) CA2330391A1 (en)
EA (1) EA200000997A1 (en)
EE (1) EE200000646A (en)
GB (1) GB9809213D0 (en)
HR (1) HRP20000732A2 (en)
HU (1) HUP0101622A3 (en)
ID (1) ID26955A (en)
IL (1) IL139181A0 (en)
IS (1) IS5675A (en)
NO (1) NO20005418L (en)
NZ (1) NZ507745A (en)
PL (1) PL343710A1 (en)
SK (1) SK16212000A3 (en)
TR (1) TR200003157T2 (en)
WO (1) WO1999055372A1 (en)
ZA (1) ZA200005922B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
WO2003090762A1 (en) * 2002-04-23 2003-11-06 Lupin Limited Long acting compositions comprising zidovudine and lamivudine
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CN100335125C (en) * 2003-06-03 2007-09-05 上海现代药物制剂工程研究中心 Interferon nasal spray powder with long service for detoxication and anti-bacteria
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
ES2279707B1 (en) * 2005-11-10 2008-06-01 Combino Pharm, S.L. ORAL FORMULATIONS THAT INCLUDE 3'-AZIDONUCLEOSIDS.
CN101878032A (en) * 2007-10-02 2010-11-03 埃默里大学 Potent combinations of zidovudine and drugs that select for the K65R mutation in the HIV polymerase
WO2009092002A1 (en) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
MX356891B (en) 2010-01-27 2018-06-19 Viiv Healthcare Co Antiviral therapy.
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
US20150104511A1 (en) 2012-03-05 2015-04-16 Cipla Limited Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
KR20150084772A (en) 2012-10-23 2015-07-22 시플라 리미티드 Pharmaceutical antiretroviral composition
NZ753904A (en) * 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
CA2330391A1 (en) 1999-11-04
IL139181A0 (en) 2001-11-25
ZA200005922B (en) 2001-10-23
BR9910071A (en) 2000-12-26
KR20010043128A (en) 2001-05-25
GB9809213D0 (en) 1998-07-01
ID26955A (en) 2001-02-22
NO20005418D0 (en) 2000-10-27
AP2000001971A0 (en) 2000-12-31
EE200000646A (en) 2002-04-15
HUP0101622A2 (en) 2002-03-28
HRP20000732A2 (en) 2001-02-28
NO20005418L (en) 2000-11-29
JP2002512979A (en) 2002-05-08
AU4135599A (en) 1999-11-16
IS5675A (en) 2000-10-20
EP1083932A1 (en) 2001-03-21
PL343710A1 (en) 2001-08-27
EA200000997A1 (en) 2001-06-25
CN1411380A (en) 2003-04-16
WO1999055372A1 (en) 1999-11-04
HUP0101622A3 (en) 2003-09-29
SK16212000A3 (en) 2001-07-10
NZ507745A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
TR200003157T2 (en) Homogeneous pharmaceutical compositions containing abacavir, lamivudine and zidovudine
DE69632256D1 (en) ANTIVIRAL PROTEINS, CODING DNA, AND THEIR USE
DE69940674D1 (en) ORAL ADMINISTRATION OF ADENOSINE ANALOG
BR9710355A (en) Useful composition for the treatment of viral infections in a mammal, process for treating a viral infection in a mammal, and, medicinal product.
TR200001892T2 (en) Insulin analogues of the genus Monomer and their use.
HUP0103423A2 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
NO20056221L (en) Modified fluorinated nucleoside analogues
RU94013464A (en) NUCLEOSIDE ANALOGUES 1,3-OXATIOLANE, METHOD OF OBTAINING, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING VIRAL INFECTION
ES2177695T3 (en) USE OF FUNCTIONAL DERIVATIVES OF THE ICAM-1 INTERCELULAR ADHESION MOLECUAL IN ANTIVIRAL THERAPY.
DK92788A (en) USE OF 3'-DEOXY-3'-FLUORUANOSIDES FOR THE PREPARATION OF MEDICINAL PRODUCTS AGAINST RETROVIRA
DE69521693D1 (en) Medicinal preparations containing taxa derivatives
BR9711647A (en) New derivatives of Dicafeoilquímica, their use, compositions with them and treatment methods using them.
EA199900345A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LAMIVUDIN AND ZIDOVUDIN
HUP0105070A2 (en) Novel treatment
DK615788A (en) NUCLEOSIDE COMPOUNDS FOR USING AGAINST VIRAL INFECTIONS
UY24930A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING (2R, CIS) -4-AMINO-1- (2-HIDROXIMETIL-1,3 -OXATIOLAN-5-IL) - (1H) -PIRIMIDIN-2-ONA (LAMIVUDINE)
AP2000001930A0 (en) AZT derivatives exhihibiting spermicidal and anti-viral activity.
BR9714279A (en) Aqueous preparation, and, use of it.
TR200101486T2 (en) Antiviral jumpsuits
AP9600896A0 (en) Anti-HIV triple combination.
AU7512287A (en) Expression of human t-cell lymphotropic virus (htlv-iii)reve rse transcriptase and uses thereof
DE69807129T2 (en) Use of a combination of beta-sitosterol and beta-sitosterol glucoside for the manufacture of a medicament for the treatment of HIV infection
BRPI0207566B8 (en) process for preparing (e)-5-(2-bromovinyl)-2'-deoxyuridine
ECSP972294A (en) PHARMACEUTICAL COMPOSITIONS
FI943295A (en) Piliostigma thonningii extracts, their use and formulations containing them